September 19, 2023

Risk Strategies Consulting Clinical Rx Pipeline Report Now Available

Consulting Pharmacy

1 min read

Stuart Piltch, President – Risk Strategies Consulting

Risk Strategies Consulting Clinical Rx Pipeline Report Now Available

Our third-quarter Clinical Pipeline Report (accessible here ) reviews multiple gene therapy approvals, the approval of first-ever treatments for ultra-rare diseases, upcoming impactful generics available (such as Vyvanse), the launch of multiple first-time biosimilars in 2024, and the race for approval to be the first gene therapy for Sickle Cell disease. As pharmacy innovation continues to rapidly develop, it is imperative to closely monitor the creation and adoption of new drugs and treatments.

Our team of expert clinical pharmacists has the necessary expertise to analyze and interpret these innovations and their corresponding impact on the healthcare marketplace. As a full-service consultancy for plan sponsors with mid-to-high aggregate drug spend, insights like these are imperative and demonstrate only a fraction of the value that our team of experts can provide to help you best navigate the way forward in this ever-changing environment.

Want to learn more?

Find Stuart Piltch on LinkedIn, here.

Learn more about our pharmacy consulting services, here.

The contents of this article are for general informational purposes only and Risk Strategies Company makes no representation or warranty of any kind, express or implied, regarding the accuracy or completeness of any information contained herein. Any recommendations contained herein are intended to provide insight based on currently available information for consideration and should be vetted against applicable legal and business needs before application to a specific client.

See all posts